Pursuant to the terms of the license agreement, Nile will pay development milestones and royalties based on sales of the licensed product.
CU-NP was designed by researchers at Mayo to combine the favorable hemodynamic venodilating effects of C-type natriuretic peptide (CNP) generated via NPR-B receptor agonism, with the beneficial renal effects of urodilatin generated via NPR-A receptor agonism.
CU-NP consists of amino acid chains identical to those produced by the human body, specifically the ring structure of C-type natriuretic peptide and the N- and C-termini of urodilatin.
Peter Strumph, CEO of Nile, said: “We are extremely excited to add CU-NP to our pipeline. With the two peptide assets, CD-NP and CU-NP, we believe Nile has the potential to develop best-in-class natriuretic peptides for multiple cardiovascular and renal indications.”